Loading...

Biocartis Group NV

BCART.BREURONEXT
Healthcare
Medical - Diagnostics & Research
0.29
0.00(0.00%)
U.S. Market opens in 3h 57m

Biocartis Group NV Fundamental Analysis

Biocartis Group NV (BCART.BR) shows weak financial fundamentals with a PE ratio of -0.27, profit margin of -1.14%, and ROE of 2.04%. The company generates $0.1B in annual revenue with N/A year-over-year growth of N/A.

Key Strengths

Cash Position148.79%
PEG Ratio-0.00
Current Ratio1.65

Areas of Concern

ROE2.04%
Operating Margin-81.85%
We analyze BCART.BR's fundamental strength across five key dimensions.

The stock receives a Fundamental Health Score of 2.7/100 based on profitability, valuation, growth, and balance sheet metrics. The F grade reflects weak fundamentals and significant financial concerns.

Fundamental Health Score

F
2.7/100

We analyze BCART.BR's fundamental strength across five key dimensions:

Efficiency Score

Weak

BCART.BR struggles to generate sufficient returns from assets.

ROA > 10%
-57.21%

Valuation Score

Excellent

BCART.BR trades at attractive valuation levels.

PE < 25
-0.27
PEG Ratio < 2
-0.00

Growth Score

Weak

BCART.BR faces weak or negative growth trends.

Revenue Growth > 5%
N/A
EPS Growth > 10%
N/A

Financial Health Score

Excellent

BCART.BR maintains a strong and stable balance sheet.

Debt/Equity < 1
-4.04
Current Ratio > 1
1.65

Profitability Score

Weak

BCART.BR struggles to sustain strong margins.

ROE > 15%
203.74%
Net Margin ≥ 15%
-1.14%
Positive Free Cash Flow
No

Key Financial Metrics

Is BCART.BR Expensive or Cheap?

P/E Ratio

BCART.BR trades at -0.27 times earnings. This suggests potential undervaluation.

-0.27

PEG Ratio

When adjusting for growth, BCART.BR's PEG of -0.00 indicates potential undervaluation.

-0.00

Price to Book

The market values Biocartis Group NV at -0.58 times its book value. This may indicate undervaluation.

-0.58

EV/EBITDA

Enterprise value stands at 1.58 times EBITDA. This is generally considered low.

1.58

How Well Does BCART.BR Make Money?

Net Profit Margin

For every $100 in sales, Biocartis Group NV keeps $-1.14 as profit after all expenses.

-1.14%

Operating Margin

Core operations generate -81.85 in profit for every $100 in revenue, before interest and taxes.

-81.85%

ROE

Management delivers $2.04 in profit for every $100 of shareholder equity.

2.04%

ROA

Biocartis Group NV generates $-57.21 in profit for every $100 in assets, demonstrating efficient asset deployment.

-57.21%

Following the Money - Real Cash Generation

Operating Cash Flow

Biocartis Group NV generates limited operating cash flow of $-69.58M, signaling weaker underlying cash strength.

$-69.58M

Free Cash Flow

Biocartis Group NV generates weak or negative free cash flow of $-72.58M, restricting financial flexibility.

$-72.58M

FCF Per Share

Each share generates $-0.77 in free cash annually.

$-0.77

FCF Yield

BCART.BR converts -1.72% of its market value into free cash.

-1.72%

Financial Ratios Analysis

Valuation Ratios

P/E Ratio

Price to earnings ratio

-0.27

vs 25 benchmark

PEG Ratio

Price/earnings to growth ratio

-0.00

vs 25 benchmark

P/B Ratio

Price to book value ratio

-0.58

vs 25 benchmark

P/S Ratio

Price to sales ratio

0.47

vs 25 benchmark

Financial Health

Debt/Equity

Total debt to shareholders' equity

-4.04

vs 25 benchmark

Current Ratio

Current assets to current liabilities

1.65

vs 25 benchmark

Efficiency Ratios

ROE

Return on equity percentage

2.04

vs 25 benchmark

ROA

Return on assets percentage

-0.57

vs 25 benchmark

ROCE

Return on capital employed

-0.65

vs 25 benchmark

How BCART.BR Stacks Against Its Sector Peers

MetricBCART.BR ValueSector AveragePerformance
P/E Ratio-0.2727.91 Better (Cheaper)
ROE203.74%687.00% Weak
Net Margin-113.74%-45285.00% (disorted) Weak
Debt/Equity-4.040.33 Strong (Low Leverage)
Current Ratio1.652795.76 Neutral
ROA-57.21%-13557.00% (disorted) Weak

BCART.BR outperforms its industry in 2 out of 6 key metrics, but lagging in ROE.

Historical Growth Performance

5-Year Growth Trajectory

This section reviews Biocartis Group NV's 5-year compound annual growth rate (CAGR) and compares its performance against the typical investment style of its industry.

Revenue CAGR

N/A

Industry Style: Defensive, Growth, Innovation

EPS CAGR

N/A

Industry Style: Defensive, Growth, Innovation

FCF CAGR

N/A

Industry Style: Defensive, Growth, Innovation

Fundamental Analysis FAQ